The Motley Fool
22 Nov 2026, 13:05 UTC · 1h ago
Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?
Impact · against what's priced in
The article provides no new catalysts for JNJ or PFE, as the reported revenue and strategic pivots are already absorbed by the current market valuations. The broader index decline reflects a systemic shift in AI sentiment that the market has already begun to price into the Mega-cap tech names.
- JNJ+0.00
Already priced in
- The price assumes
The delivered 6.0% revenue growth across both segments





